Amgen Inc. (NASDAQ:AMGN - Get Free Report) SVP Nancy Grygiel sold 1,237 shares of the firm's stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Amgen Stock Up 1.8%
Amgen stock opened at $329.59 on Wednesday. The company has a debt-to-equity ratio of 5.65, a quick ratio of 0.90 and a current ratio of 1.26. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29. The company has a 50-day simple moving average of $357.16 and a 200-day simple moving average of $341.35. The firm has a market capitalization of $177.87 billion, a P/E ratio of 22.94, a P/E/G ratio of 3.08 and a beta of 0.44.
Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.77 by $0.38. The firm had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. Amgen's quarterly revenue was up 5.8% compared to the same quarter last year. During the same period last year, the firm posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities analysts expect that Amgen Inc. will post 22.45 earnings per share for the current year.
Amgen Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 3.1%. Amgen's payout ratio is currently 70.15%.
Analysts Set New Price Targets
Several analysts recently commented on AMGN shares. Deutsche Bank Aktiengesellschaft raised their target price on Amgen from $285.00 to $295.00 and gave the company a "hold" rating in a research report on Thursday, February 5th. Leerink Partners reissued a "market perform" rating and issued a $355.00 price target on shares of Amgen in a research note on Thursday, March 5th. Rothschild & Co Redburn raised their price target on Amgen from $180.00 to $200.00 and gave the company a "sell" rating in a report on Wednesday, February 18th. TD Cowen restated a "buy" rating on shares of Amgen in a research note on Wednesday, February 4th. Finally, Sanford C. Bernstein downgraded shares of Amgen from an "outperform" rating to a "market perform" rating and set a $335.00 price objective for the company. in a report on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fifteen have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $357.12.
View Our Latest Research Report on Amgen
Trending Headlines about Amgen
Here are the key news stories impacting Amgen this week:
- Positive Sentiment: Amgen announced a $300 million additional U.S. manufacturing investment (Puerto Rico) to expand biologics capacity and strengthen supply-chain resilience; investors tend to see such capital spending as supportive of long-term growth and reliability. Article Title
- Neutral Sentiment: Erste Group reaffirmed a "hold" rating on AMGN, signaling no change in near-term analyst conviction and limiting directional impact from that broker. Article Title
- Neutral Sentiment: Market/sector headwinds: healthcare stocks were softer in recent trading sessions, a background factor that can mute upside for AMGN even as company-specific news emerges. Article Title
- Negative Sentiment: Competitive risk: Viridian Therapeutics reported encouraging results for its chronic thyroid eye disease program, a potential rival to Amgen’s Tepezza — the data lifted Viridian shares and raises the probability of increased market competition for Tepezza sales over time. Article Title
- Negative Sentiment: Guggenheim trimmed its price target on AMGN to $340 (from $351) while keeping a Neutral rating — a modest lowering of upside that can cap near-term analyst-driven buying. Article Title
Institutional Investors Weigh In On Amgen
Institutional investors have recently added to or reduced their stakes in the company. Anfield Capital Management LLC boosted its stake in Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company's stock valued at $25,000 after buying an additional 70 shares in the last quarter. Dogwood Wealth Management LLC raised its position in Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company's stock worth $25,000 after acquiring an additional 55 shares in the last quarter. Board of the Pension Protection Fund acquired a new stake in Amgen in the 4th quarter valued at about $26,000. Tower View Wealth Management LLC lifted its holdings in Amgen by 331.6% in the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company's stock valued at $29,000 after acquiring an additional 63 shares during the last quarter. Finally, Manning & Napier Advisors LLC boosted its position in shares of Amgen by 49.2% during the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company's stock valued at $32,000 after purchasing an additional 32 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.
Amgen Company Profile
(
Get Free Report)
Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.
Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
